FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and medicine, in particular to a single-chain fusion protein for inhibiting the cellular secretion of a target cell, a nucleic acid, an expression vector, a method for producing a fusion protein and a three-chain non-cytotoxic protein under the action of a protease on a fusion protein, as well as the use of proteins of the invention for the treatment of pathophysiological conditions associated with cellular hypersecretion. Said protein includes a non-cytotoxic protease, a targeting moiety, that is capable of binding to a binding site on the target cell, a translocation domain that is capable of translocating the protease into the cytosol of the target cell, two protease cleavage sites and a covalent bond between the targeting moiety and the translocation domain.
EFFECT: present invention improves binding due to the presence of certain targeting moieties in the fusion protein structure.
23 cl, 1 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| SUPPRESSION OF ALLODYNIA INDUCED BY BONE CANCER | 2019 |
|
RU2791640C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
